{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:23:37Z","timestamp":1786487017240,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Anamorelin was approved for production and marketing in Japan on 22 January 2021 for cancer cachexia in non-small-cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. The authors describe the updates of anamorelin for cancer cachexia in Japan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent evidence showed that anamorelin improved lean body mass, body weight, and appetite in patients with cancer cachexia in clinical practice. Anamorelin does not increase body weight in the severe-weight-loss group in cachectic patients with pancreatic cancer. Several case reports showed that anamorelin can cause cardiac adverse drug reactions. Among the cardiac adverse reactions, fatal arrhythmias should be monitored carefully even if it is the first dose. Anamorelin combined with nutrition, physical activity, and exercise may be more useful than anamorelin alone for treating cancer cachexia. An interim analysis from post-marketing all-case surveillance was performed; however, details have not yet been published. When anamorelin cannot be used for cancer cachexia, Kampo medicines can be considered as an option.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Anamorelin has changed the clinical practice of cancer cachexia in Japan. The authors hope that anamorelin is available for other disease-related cachexia along with appropriate multidisciplinary interventions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000658","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T15:04:30Z","timestamp":1688137470000},"page":"162-167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Anamorelin in Japanese patients with cancer cachexia: an update"],"prefix":"10.1097","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-0818","authenticated-orcid":false,"given":"Hidetaka","family":"Wakabayashi","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine, Tokyo Women\u2019s Medical University Hospital, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[{"name":"National Center for Geriatrics and Gerontology, Aichi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Inui","sequence":"additional","affiliation":[{"name":"Pharmacological Department of Herbal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"R1-20250525","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"R2-20250525","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jcsm.12675","article-title":"The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers","volume":"12","author":"Wakabayashi","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R3-20250525","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1254\/fpj.21046","article-title":"Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ\u00aeTablets), the first orally available drug for cancer cachexia with ghrelin-like action in Japan","volume":"156","author":"Nakanishi","year":"2021","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"R5-20250525","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/cncr.34154","article-title":"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index","volume":"128","author":"Naito","year":"2022","journal-title":"Cancer"},{"key":"R6-20250525","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1002\/cam4.5206","article-title":"Efficacy and safety of anamorelin in patients with cancer cachexia: post-hoc subgroup analyses of a placebo-controlled study","volume":"12","author":"Takayama","year":"2023","journal-title":"Cancer Med"},{"key":"R7-20250525","article-title":"Impact of the extent of weight loss before administration on the efficacy of anamorelin in advanced pancreatic cancer patients with cachexia","author":"Takeda","year":"2022","journal-title":"Intern Med"},{"key":"R8-20250525","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2169\/internalmedicine.9322-22","article-title":"Refractory monomorphic ventricular tachycardia induced by anamorelin","volume":"62","author":"Sakagami","year":"2023","journal-title":"Intern Med"},{"key":"R9-20250525","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jccase.2022.04.015","article-title":"Two cases of wide QRS complex tachycardia caused by anamorelin","volume":"26","author":"Okidono","year":"2022","journal-title":"J Cardiol Cases"},{"key":"R10-20250525","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.hrcr.2022.12.011","article-title":"First case report of anamorelin-induced fatal arrhythmia complicated by sinus arrest and refractory ventricular tachycardia","volume":"9","author":"Kojima","year":"2022","journal-title":"HeartRhythm Case Rep"},{"key":"R13-20250525","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-021-06463-8","article-title":"Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study","volume":"30","author":"Yennurajalingam","year":"2022","journal-title":"Support Care Cancer"},{"key":"R14-20250525","first-page":"101609","article-title":"A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia","volume":"36","author":"Oshima","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"R15-20250525","article-title":"Real-world safety and effectiveness of anamorelin in patients with cancer cachexia in Japan: an interim analysis from post-marketing all-case surveillance (O077-1)","author":"Takayama","journal-title":"The Japan Society of Clinical Oncology"},{"key":"R16-20250525","article-title":"Real-world outcomes of anamorelin in patients with non-small cell lung cancer in Japan (O58-1)","author":"Takayama","journal-title":"The Japan Lung Cancer Society Online Journal"},{"key":"R18-20250525","first-page":"167","article-title":"Sarcopenia and cachexia evaluation in different healthcare settings: a questionnaire survey of health professionals","volume":"27","author":"Nakahara","year":"2018","journal-title":"Asia Pac J Clin Nutr"},{"key":"R19-20250525","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1002\/jcsm.13105","article-title":"Identification and management of cancer cachexia in patients: assessment of healthcare providers\u2019 knowledge and practice gaps","volume":"13","author":"Baracos","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R20-20250525","doi-asserted-by":"crossref","first-page":"102188","DOI":"10.1016\/j.npep.2021.102188","article-title":"Application of Kampo medicines for the palliation of cancer cachexia","volume":"90","author":"Ohsawa","year":"2021","journal-title":"Neuropeptides"},{"key":"R21-20250525","doi-asserted-by":"crossref","first-page":"100839","DOI":"10.1016\/j.imr.2022.100839","article-title":"Kampo medicines for supportive care of patients with cancer: a brief review","volume":"11","author":"Motoo","year":"2022","journal-title":"Integr Med Res"},{"key":"R22-20250525","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MCO.0000000000000787","article-title":"Rehabilitation nutrition for individuals with frailty, disability, sarcopenic dysphagia, or sarcopenic respiratory disability","volume":"25","author":"Mizuno","year":"2022","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R23-20250525","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/nutrit\/nuac047","article-title":"Interaction between malnutrition and physical disability in older adults: is there a malnutrition-disability cycle?","volume":"81","author":"Nishioka","year":"2023","journal-title":"Nutr Rev"},{"key":"R24-20250525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5534\/wjmh.200190","article-title":"Rehabilitation nutrition and exercise therapy for sarcopenia","volume":"40","author":"Kakehi","year":"2022","journal-title":"World J Mens Health"},{"key":"R25-20250525","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.3390\/nu13061961","article-title":"Polypharmacy and malnutrition management of elderly perioperative patients with cancer: a systematic review","volume":"13","author":"Kose","year":"2021","journal-title":"Nutrients"},{"key":"R26-20250525","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/jgf2.549","article-title":"Diagnostic reasoning in rehabilitation nutrition: position paper by the Japanese Association of Rehabilitation Nutrition (secondary publication)","volume":"23","author":"Wakabayashi","year":"2022","journal-title":"J Gen Fam Med"},{"key":"R27-20250525","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jgf2.509","article-title":"Goal setting for nutrition and body weight in rehabilitation nutrition: position paper by the Japanese Association of Rehabilitation Nutrition (secondary publication)","volume":"23","author":"Wakabayashi","year":"2021","journal-title":"J Gen Fam Med"},{"key":"R28-20250525","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clnesp.2022.09.013","article-title":"The concept of aggressive nutrition therapy and clinical indication: a position paper","volume":"52","author":"Nishioka","year":"2022","journal-title":"Clin Nutr ESPEN"},{"key":"R29-20250525","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clnesp.2021.02.018","article-title":"Clinical practice guidelines for rehabilitation nutrition in cerebrovascular disease, hip fracture, cancer, and acute illness: 2020 update","volume":"43","author":"Nishioka","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"R30-20250525","first-page":"243","article-title":"Nutrition and physical therapy: a position paper by the Physical Therapist Section of the Japanese Association of Rehabilitation Nutrition (Secondary Publication)","volume":"5","author":"Inoue","year":"2022","journal-title":"JMA J"},{"key":"R31-20250525","first-page":"252","article-title":"Disease-specific nutritional physical therapy: a position paper by the Japanese Association of Rehabilitation Nutrition (Secondary Publication)","volume":"5","author":"Inoue","year":"2022","journal-title":"JMA J"},{"key":"R32-20250525","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jgf2.567","article-title":"Positive psychology and rehabilitation nutrition","volume":"23","author":"Wakabayashi","year":"2022","journal-title":"J Gen Fam Med"},{"key":"R33-20250525","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ggi.14519","article-title":"Respiratory sarcopenia: a position paper by four professional organizations","volume":"23","author":"Sato","year":"2023","journal-title":"Geriatr Gerontol Int"},{"key":"R34-20250525","doi-asserted-by":"crossref","first-page":"e000551","DOI":"10.1136\/bmjresp-2019-000551","article-title":"Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol","volume":"7","author":"Hoon","year":"2020","journal-title":"BMJ Open Respir Res"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:04:17Z","timestamp":1748196257000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000658","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}